John-Paul Pham, MD
Interventional Cardiology · Jacksonville, FLNPI 1841491503
Payments from drug & device makers
Across 286 payments — averaging $27.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Abiomed$1K
- Abbott$637
- Cvrx, Inc.$482
- Edwards Lifesciences$471
- AstraZeneca$404
- plus $3K from 27 others
What the payments were for
- Travel & lodging$1852%
- Food & beverage$7,75197%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 66 | $1,899 |
| Abiomed | 12 | $1,045 |
| Abbott | 9 | $637 |
| Cvrx, Inc. | 5 | $482 |
| Edwards Lifesciences | 3 | $471 |
| AstraZeneca | 13 | $404 |
| Amgen | 16 | $282 |
| Stryker | 66 | $272 |
| Shockwave Medical, Inc | 8 | $254 |
| Medtronic | 3 | $201 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $195 |
| Inari Medical, Inc. | 1 | $184 |
| Angiodynamics, Inc. | 3 | $177 |
| Johnson & Johnson | 5 | $174 |
| Boehringer Ingelheim | 10 | $168 |
| Penumbra, Inc. | 9 | $152 |
| Novartis | 9 | $145 |
| Pfizer | 8 | $138 |
| Merck | 4 | $138 |
| Opsens Inc. | 1 | $122 |
| Bard Peripheral Vascular, Inc. | 4 | $86 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $50 |
| Endovascular Engineering Inc. | 1 | $49 |
| Bayer | 2 | $46 |
| Philips North America LLC | 2 | $36 |
| Heartflow, Inc. | 1 | $35 |
| Impulse Dynamics (USA) Inc. | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| GSK | 1 | $20 |
| Novo Nordisk | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| Terumo Medical Corporation | 1 | $13 |
| Irhythm Technologies, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$666
- Barostim Neo System$441
- FLOWTRIEVER CATHETER, S$184
- CT THROMBECTOMY SYSTEM KIT$184
- Edwards SAPIEN XT Transcatheter Heart Valve$181
- Edwards SAPIEN 3 Transcatheter Heart Valve$168
- MitraClip System$163
- WATCHMAN FLX$147
- WATCHMAN Access System$141
- MitraClip$127
- AMPLATZER AMULET$123
- SAPIEN 3 Ultra RESILIA$123
- OptoWire$122
- OptoMonitor$122
- Vascular Lithotripsy$119
- BRILINTA$118
- COREVALVE EVOLUT R$118
- FARXIGA$116
- XARELTO$113
- AlphaVac$105
How this compares
$7,976 in reported general payments places this provider in the 45th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 106 | $107,894 |
| EntrestoSacubitril/Valsartan | 69 | $92,069 |
| XareltoRivaroxaban | 70 | $91,529 |
| JardianceEmpagliflozin | 48 | $58,015 |
| Repatha SureclickEvolocumab | 67 | $50,878 |
| FarxigaDapagliflozin Propanediol | 25 | $33,075 |
| VerquvoVericiguat | 20 | $29,998 |
| BrilintaTicagrelor | 15 | $19,279 |
| Atorvastatin Calcium | 160 | $2,051 |
| Midodrine Hcl | 16 | $1,875 |
| Metoprolol Succinate | 106 | $1,222 |
| Hydralazine Hcl | 27 | $1,039 |
| Losartan Potassium | 89 | $867 |
| Carvedilol | 80 | $852 |
| Amiodarone Hcl | 18 | $779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $138 | $107,894106 claims |
| NovartisEntresto | $145 | $92,06969 claims |
| Johnson & JohnsonXarelto | $174 | $91,52970 claims |
| Boehringer IngelheimJardiance | $168 | $58,01548 claims |
| AstraZenecaFarxiga, Brilinta | $404 | $52,35440 claims |
| MerckVerquvo | $138 | $29,99820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Jacksonville
- Dominick AngiolilloJacksonville$4M
- Ruby SatpathyJacksonville$1.8M
- Siddharth WayangankarJacksonville$1.3M
- Sumant LambaJacksonville$862K
- Yazan KhatibJacksonville$588K
- Bharat GummadiJacksonville$339K
- Salil PatelJacksonville$306K
- Raguveer MurthyJacksonville$249K
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.